Wake Forest Atrium HeartShare Clinical Center

维克森林中庭 HeartShare 临床中心

• 批准号: 10678972
• 负责人: DALANE W KITZMAN
• 金额: $ 27.47万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-10 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10678972
• 关键词: Abdomen; Acceleration; Address; Adipose tissue; Age; Aging; Aorta; Artificial Intelligence; Biological; Biological Markers; Biopsy; Blood; Blood Vessels; Body Composition; Brain; Cardiac; Clinical; Cognition; Collaborations; Complement; Consensus; Consent; Control Groups; Creativeness; DNA; Data; Development; Diabetes Mellitus; EFRAC; Educational workshop; Electrocardiogram; Electronic Health Record; Enrollment; Ensure; Evidence based treatment; Functional disorder; Funding; Future; Genetic Materials; Goals; Health; Health system; Heart; Heart Atrium; Heart failure; Heterogeneity; Hypertension; Image; Institution; International; Intervention; Lead; Leadership; Lung; Machine Learning; Magnetic Resonance Imaging; Mental Depression; Mitochondria; Monitor; Morbidity - disease rate; Muscle; Obesity; Outcome; Paper; Participant; Pathogenesis; Patient Recruitments; Patients; Phase; Phenotype; Physical activity; Plasma; Population Heterogeneity; Population Study; Prevalence; Prognosis; Protocols documentation; Qualifying; Quality of life; Recommendation; Reporting; Research Personnel; Research Priority; Resources; Sampling; Seminal; Serum; Signal Transduction; Skeletal Muscle; Specimen; Structure; Syndrome; Techniques; Testing; Thigh structure; Tissue Sample; United States National Institutes of Health; Visit; Work; actigraphy; bioinformatics tool; cardiac magnetic resonance imaging; career; clinical center; cohort; comorbidity; data repository; deep learning; design; experience; forest; frailty; gender diversity; innovation; insight; microbiome; mortality; multidisciplinary; new therapeutic target; novel; preservation; primary outcome; programs; prospective; racial diversity; randomized trial; recruit; response; retention rate; signal processing; success; therapeutic target

Project Summary Heart Failure with Preserved Ejection Fraction (HFpEF) is the most common form of HF in the US and is associated with high morbidity and mortality. However, its pathophysiology is incompletely understood, and most trials have been neutral such that few evidence-based treatments exist. In response, NIH convened 2 workshops co-led by Dr. Kitzman (PI). The highest priority research recommendation was a coordinated effort to create a large cohort of HFpEF patients and controls and perform comprehensive, deep phenotyping. This became the basis for HeartShare, whose ultimate goals are to discover novel HFpEF mechanisms, subtypes, and therapeutic targets. Our Wake Forest - Atrium HFpEF team is highly qualified to serve as a Clinical Center and make robust, over-arching contributions to HeartShare. Dr. Kitzman is internationally recognized as a thought-leader in HFpEF with a sustained track record of developing novel concepts regarding HFpEF pathogenesis, mechanisms, and outcomes and designing and conducting innovative studies to test them. His team has extensive experience in all key aspects of the HeartShare program, particularly in recruiting, retaining, and phenotyping diverse populations of HFpEF patients and controls, often significantly exceeding goals for racial and gender diversity. Our institutions have ~15,000 HFpEF clinical visits annually. In all, our team has led or helped lead recruitment and phenotyping for 69 studies, mostly NIH-sponsored, with 15,354 participants, demonstrating our ability to fulfill HeartShare recruitment and phenotyping goals. Data from these studies will be contributed to the Cohort phase of HeartShare. We will make robust contributions to HeartShare by achieving 4 Specific Aims: Aim 1) Provide ‘thought leadership’ in collaboration with the HeartShare Steering Committee; Aim 2) Contribute data, images, and stored specimens cohort phase of HeartShare from our numerous studies of HFpEF and controls, and identify and phenotype HFpEF patients and controls from the electronic health record using robust bioinformatics tools; Aim 3) Recruit, consent, enroll and follow at least 250 HFpEF patients plus controls (type and number to be determined by consensus); Aim 4) Conduct state-of- the-art deep phenotyping exams using a collaboratively determined protocol. Our phenotyping proposal is highly innovative, with advanced echo-Doppler and cardiac magnetic resonance imaging, CPET, physical activity monitoring, remote and artificial intelligence electrocardiography, sampling of skeletal muscle, adipose, blood, and microbiome, and mitochondrial energetics, and brain structure/function. Our diverse, cross- disciplinary team has the full range of complementary expertise and access to the robust resources of two large, closely affiliated health systems to ensure fulfillment of all HeartShare’s goals. We will help accelerate and optimize the program’s success with our insight, creativity, and sustained track record of collaboration, innovation, and dissemination.

项目概要 射血分数保留的心力衰竭 (HFpEF) 是美国最常见的 HF 形式， 与高发病率和死亡率相关。然而，其病理生理学尚不完全清楚，并且 大多数试验都是中立的，因此很少有基于证据的治疗方法。作为回应，NIH 召开了 2 由 Kitzman 博士（PI）共同领导的研讨会。最优先的研究建议是协调一致的努力 创建一大群 HFpEF 患者和对照，并进行全面、深入的表型分析。这 成为 HeartShare 的基础，其最终目标是发现新的 HFpEF 机制、亚型、 和治疗目标。我们的 Wake Forest - Atrium HFpEF 团队非常有资格担任临床中心 并为 HeartShare 做出强有力的、全面的贡献。 Kitzman 博士是国际公认的 HFpEF 领域的思想领袖，在开发有关 HFpEF 的新颖概念方面拥有持续的记录 发病机制、机制和结果，并设计和开展创新研究来测试它们。他的 团队在 HeartShare 计划的所有关键方面都拥有丰富的经验，特别是在招聘、 保留 HFpEF 患者和对照的不同群体并对其进行表型分析，通常显着超过 种族和性别多样性的目标。我们的机构每年约有 15,000 次 HFpEF 临床就诊。总而言之，我们的 团队领导或帮助领导了 69 项研究的招募和表型分析，其中大部分是 NIH 赞助的，涉及 15,354 项研究 参与者，展示了我们实现 HeartShare 招募和表型分析目标的能力。数据来自这些 研究将有助于 HeartShare 的队列阶段。我们将为 HeartShare 做出积极贡献 通过实现 4 个具体目标： 目标 1) 与 HeartShare Steering 合作提供“思想领导力” 委员会;目标 2) 贡献来自我们的 HeartShare 的数据、图像和存储的样本队列阶段 对 HFpEF 和对照进行了大量研究，并从 HFpEF 患者和对照中识别和表型 使用强大的生物信息学工具的电子健康记录；目标 3) 至少招募、同意、登记和关注 250 名 HFpEF 患者加上对照（类型和数量由共识确定）；目标 4) 进行状态- 使用协作确定的协议进行最先进的深度表型分析检查。我们的表型分析建议是 高度创新，具有先进的回声多普勒和心脏磁共振成像、CPET、物理 活动监测、远程和人工智能心电图、骨骼肌、脂肪采样、 血液、微生物组、线粒体能量学和大脑结构/功能。我们多元化、跨领域 学科团队拥有全方位的互补专业知识，并可利用两个团队的强大资源 大型、密切相关的卫生系统，以确保实现 HeartShare 的所有目标。我们将帮助加速 并利用我们的洞察力、创造力和持续的合作记录来优化该计划的成功， 创新、传播。